[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 231
Citations 0
Capitol Health Call
April 10, 2013

Animal Drug Regulation

JAMA. 2013;309(14):1452. doi:10.1001/jama.2013.2985

Interested parties hope to see reauthorization of the Food and Drug Administration (FDA) animal drug user fee agreements, which are set to expire on October 1. Proponents spoke February 27 before the Senate Committee on Health, Education, Labor, and Pensions.

The Animal Drug User Fee Agreement and Animal Generic Drug User Fee Agreement programs mirror the programs for human medical products. The agreements allow the FDA to collect fees from sponsors of animal drug and animal generic drug applications, and the agency uses those fees to help fund review of the applications.